Form 8-K

MERRIMACK PHARMACEUTICALS, INC.

Date: June 16, 2016

/s/ Jeffrey A. Munsie

Jeffrey A. Munsie

General Counsel

0001193125-16-623729.txt : 20160616 0001193125-16-623729.hdr.sgml : 20160616 20160616165501 ACCESSION NUMBER: 0001193125-16-623729 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160614 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders FILED AS OF DATE: 20160616 DATE AS OF CHANGE: 20160616 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERRIMACK PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001274792 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35409 FILM NUMBER: 161718077 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: SUITE B7201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-441-1000 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: SUITE B7201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 8-K 1 d213847d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 14, 2016

Merrimack Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in its Charter)


Delaware	001-35409	04-3210530
(State or Other Jurisdiction of Incorporation	(Commission File Number)	(IRS Employer Identification No.)

One Kendall Square, Suite B7201 Cambridge, MA		02139
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 441-1000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07. Submission of Matters to a Vote of Security Holders.

At the 2016 Annual Meeting of Stockholders of Merrimack Pharmaceuticals, Inc. (the “Company”) held on June 14, 2016, the Company’s stockholders voted as follows:

1. The stockholders elected the nominees listed below to the Company’s board of directors (the “Board”), each for a one year term ending at the Company’s 2017 annual meeting of stockholders.


Nominees	For		Withheld		Broker Non-Votes
Robert J. Mulroy		58,623,214		5,842,601		36,846,074
Gary L. Crocker		58,518,596		5,947,219		36,846,074
John M. Dineen		64,172,341		293,474		36,846,074
Vivian S. Lee, M.D., Ph.D.		64,161,867		303,948		36,846,074
John Mendelsohn, M.D.		64,132,183		333,632		36,846,074
Ulrik B. Nielsen, Ph.D.		64,165,902		299,913		36,846,074
Michael E. Porter, Ph.D.		58,594,291		5,871,524		36,846,074
James H. Quigley		64,176,146		289,669		36,846,074
Russell T. Ray		64,177,124		288,691		36,846,074

2. The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers.


For:			58,015,933
Against:			3,287,675
Abstain:			3,162,207
Broker Non-Votes:			36,846,074

3. The stockholders ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016.


For:			100,263,104
Against:			926,291
Abstain:			122,494

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.